Related Experiment Video
Updated: Jul 13, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
[Stroke. Diagnosis and therapeutic management of cerebrovascular disease]
Xavier Ustrell-Roig1, Joaquín Serena-Leal
1Servicio de Neurología, Hospital de Sant Pau i Santa Tecla, Tarragona, España.
Insights
Stroke is a leading cause of death and disability. Advanced treatments like thrombolysis and specialized stroke units improve patient outcomes and reduce mortality.
Area of Science:
- Neurology
- Cardiovascular Medicine
Context:
- Stroke is a major global health challenge, ranking as the second leading cause of death and the primary cause of disability.
- It imposes a significant economic burden due to long-term care and lost productivity.
Purpose:
- To review current and emerging strategies for acute stroke treatment and prevention.
- To highlight the importance of protocolized management in stroke units.
Summary:
- Recombinant tissue plasminogen activator (rtPA) is effective within 3 hours post-stroke, with regulatory approval from FDA and EMEA.
- Stroke units implement protocolized acute phase management, reducing mortality and disability.
- Ongoing research focuses on extended therapeutic windows, combined thrombolysis techniques, advanced neuroimaging for patient selection, and neuroprotective therapies.
Impact:
- Advances in stroke treatment and prevention are shifting therapeutic attitudes from nihilistic to active management.
- Improved understanding of cerebrovascular disease, risk factors, and new drugs enhance preventive strategies.
- This evolving knowledge is crucial for optimizing patient care and outcomes in cerebrovascular diseases.
Abstract:
Stroke is the second cause of death and the first cause of disability with an important economical cost. Thrombolysis and stroke units are the major contribution to stroke treatment of the last years changing a nihilist therapeutic attitude towards an active attitude, stroke is a medical emergency. Treatment with rtPA has shown to be effective in the first 3 hours following stroke and the FDA and the European Medical Agency (EMEA) have approved its use. A protocolised management of the acute phase to treat physiological complications is the mainstone of stroke units showing a reduction in mortality and disability. Multiple strategies are under development in order to treat more patients, drugs with a longer therapeutic window, intravenous thrombolysis followed by intrarterial thrombolysis, selection of patients with mismatch with new neuroimaging techniques and neuroprotective therapies. Preventive treatment has also experienced a change due to a better knowledge of the ethiopathogeny, the role of vascular risk factors and the development of new preventive drugs. Knowledge of cerebrovascular diseases is today's clue for the best treatment of our patients.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Ischemic Stroke l: Introduction
Stroke: Introduction and Types
Atherosclerosis IV: Nursing Management
Transient Ischemic Attack l: Introduction
Hemorrhagic Stroke l: Introduction
